Axitinib

What it is used for

INLYTA is a kinase inhibitor indicated: in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

First-Line Advanced Renal Cell Carcinoma INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced RCC. Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.

Side effects, and when to stop

The following clinically significant adverse reactions are discussed elsewhere in the labeling:

• Hypertension
• Arterial thromboembolic events
• Venous thromboembolic events
• Hemorrhage
• Cardiac failure
• Gastrointestinal perforation and fistula formation
• Thyroid dysfunction
• Reversible posterior leukoencephalopathy syndrome
• Proteinuria
• Hepatotoxicity
• Hepatic impairment

Who should not take it

None.